- Home
- PASG vs NRSN Comparison
PASG vs NRSN Comparison
Compare PASG & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PASG
- NRSN
- Stock Information
- Founded
- PASG 2017
- NRSN 2017
- Country
- PASG United States
- NRSN Israel
- Employees
- PASG N/A
- NRSN N/A
- Industry
- PASG Biotechnology: Pharmaceutical Preparations
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- PASG Health Care
- NRSN Health Care
- Exchange
- PASG Nasdaq
- NRSN Nasdaq
- Market Cap
- PASG 27.6M
- NRSN 29.8M
- IPO Year
- PASG 2020
- NRSN 2021
- Fundamental
- Price
- PASG $7.32
- NRSN $1.08
- Analyst Decision
- PASG Strong Buy
- NRSN Buy
- Analyst Count
- PASG 4
- NRSN 2
- Target Price
- PASG $59.25
- NRSN $14.00
- AVG Volume (30 Days)
- PASG 37.0K
- NRSN 200.4K
- Earning Date
- PASG 11-17-2025
- NRSN 12-17-2025
- Dividend Yield
- PASG N/A
- NRSN N/A
- EPS Growth
- PASG N/A
- NRSN N/A
- EPS
- PASG N/A
- NRSN N/A
- Revenue
- PASG N/A
- NRSN N/A
- Revenue This Year
- PASG N/A
- NRSN N/A
- Revenue Next Year
- PASG N/A
- NRSN N/A
- P/E Ratio
- PASG N/A
- NRSN N/A
- Revenue Growth
- PASG N/A
- NRSN N/A
- 52 Week Low
- PASG $5.12
- NRSN $0.80
- 52 Week High
- PASG $26.60
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- PASG 43.77
- NRSN 41.00
- Support Level
- PASG $6.82
- NRSN $1.03
- Resistance Level
- PASG $7.90
- NRSN $1.30
- Average True Range (ATR)
- PASG 0.64
- NRSN 0.08
- MACD
- PASG -0.13
- NRSN -0.01
- Stochastic Oscillator
- PASG 23.04
- NRSN 24.53
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.